Advertisements

Uro Cefasabal NF

Quick links to important sections

Uro Cefasabal NF

Advertisements
Advertisements

Method of action: Bactericidal

Treatment option: Prostatitis, Urethritis, Cystitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Uro Cefasabal NF

Property Description
Active Ingredient Pipemidic Acid
Form Oral Capsules or Tablets
Pharmacological Class Quinolone Antibiotic (Urinary Tract Anti-Infective)
Common Use Treatment of specific bacterial urinary tract infections
Regulatory Status Prescription-only medicine (Rx)

Uro Cefasabal NF is a specific brand formulation containing the active ingredient Pipemidic Acid, a synthetic antibiotic used primarily for treating infections within the urinary system. Unlike over-the-counter supplements, this product is classified as a prescription medicine and is typically supplied as oral capsules or tablets containing 400 mg of the active agent.

Pipemidic Acid is structurally part of the quinolone class, which is clinically recognized for its effectiveness against a range of common pathogens that cause urinary tract infections (UTIs). Its composition makes it a targeted treatment, often prescribed in cases of bacterial cystitis or prostatitis where the causative bacteria are known to be sensitive to this specific agent.


Which Pharmacological Class Does Uro Cefasabal NF Belong To?

Uro Cefasabal NF is categorized as a Quinolone Antibiotic, specifically functioning as a urinary tract anti-infective. This classification signifies that its general therapeutic purpose is the definitive elimination or suppression of bacterial pathogens within the urinary tract.

The antibiotic operates by inhibiting the essential enzymes required for bacterial DNA replication. This mechanism is crucial for clearing established acute and chronic infections, thereby fundamentally distinguishing it from supportive nutraceuticals or general health supplements.


Who is Uro Cefasabal NF For?

This medication is strictly intended for adult patients diagnosed with acute, chronic, or recurrent urinary tract infections that have been confirmed or are strongly suspected to be caused by susceptible organisms. As a prescription-only medicine, Uro Cefasabal NF must only be used under the direction and supervision of a qualified physician who has determined the appropriate clinical need based on patient diagnostics.

Advertisements

What side effects are possible with Uro Cefasabal NF?

Possible side effects and safety information

Uro Cefasabal NF contains Pipemidic Acid, a quinolone antibiotic. The official safety information for this class of medicine, as documented by government regulatory authorities, details a safety profile organized by the body system affected and a focus on serious, potentially permanent adverse reactions.

Systemic Safety Classifications

Adverse reactions are classified into high-level categories based on the physiological systems involved, including Musculoskeletal and Connective Tissue Disorders, Nervous System Disorders, Gastrointestinal Disorders, and Cardiac Disorders. The most frequently reported adverse reactions listed in official documents include nausea, diarrhea, headache, dizziness, and trouble sleeping (insomnia).

Serious Adverse Reactions and Safety Patterns

Regulatory documentation highlights the risk of disabling and potentially permanent adverse effects involving the tendons, muscles, joints, nerves, and central nervous system. Specific serious reactions documented for this class include tendonitis and tendon rupture, peripheral neuropathy (tingling or numbness in the limbs), and serious central nervous system effects such as psychosis or confusion. These serious effects can manifest hours after treatment begins or up to several months after treatment completion, a time-related pattern explicitly noted in regulatory safety communications.

Population-Specific Safety Considerations

Official labels identify specific patient populations that may be at increased risk. For example, older patients (typically over 60 years of age) and those taking concomitant corticosteroids have a higher documented risk for severe tendon disorders. Due to the nature of the serious risks, regulatory bodies advise restricting the use of this class of antibiotics for certain uncomplicated infections when alternative treatments are available.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented approach to an overdose of Uro Cefasabal NF (Pipemidic Acid) based on government regulatory guidance.

Documented Manifestations and Emergency Actions

To date, specific incidents of poisoning from this medication have not been formally reported. However, in the event of massive absorption of the drug, clinical signs related to the quinolone class of antibiotics may occur. Potential signs could involve the neurological system, such as dizziness or balance disorders.

Because of the potential for serious outcomes, if signs of massive dose absorption are observed, immediate medical attention is required for assessment and management. The regulatory guidance mandates that the usual emergency measures be implemented by healthcare professionals.

Officially Described Overdose Management

There is no specific antidote documented for Pipemidic Acid overdose. Management is entirely supportive and procedural:

  • Gastric Lavage: Recommended if the overdose ingestion is recent.
  • Forced Diuresis: Recommended if the product has already been absorbed.
  • Resuscitation: Must be administered if deemed clinically necessary.

These mandated procedures reinforce the need for urgent hospitalization and professional medical monitoring should an overdose be suspected.

Advertisements

Therapeutic Uses of Uro Cefasabal NF

Uro Cefasabal NF (Pipemidic Acid) is a targeted antibiotic generally used in adult patients for managing specific bacterial infections within the urinary system and associated reproductive structures. Its therapeutic application is relevant in addressing susceptible pathogens to support infection management and contribute to easing the overall symptom load. The medication is commonly used to help with urinary tract infections (UTIs) caused by susceptible organisms.


Therapeutic Focus and Symptom Relief

This medicine is applied across therapeutic domains involving distressing symptoms of the lower urinary tract, particularly for acute cystitis, recurrent urinary tract infections, and complex infections like bacterial prostatitis in adult men. Uro Cefasabal NF primarily addresses the pronounced symptom clusters that interfere with daily functioning, such as the pain or burning sensation during urination (dysuria), increased urinary frequency and urgency, and localized discomfort like perineal pain associated with prostate infection. It is relevant when supportive symptom management is appropriate, applied during phases when symptoms become more noticeable due to active bacterial presence.

In situations where symptoms are linked to active infection, the medication provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms and helping patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Irritative Symptoms This medicine is commonly used to help with symptoms related to inflammatory or irritative states of the urinary tract, assisting patients in managing symptoms that become more disruptive during flare-ups.

Advertisements

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

This section outlines the officially documented eligibility rules and absolute contraindications for Uro Cefasabal NF (Pipemidic Acid) as defined by regulatory authorities. The medicine's use is generally established for adult patients diagnosed with susceptible urinary tract infections.


Absolute Contraindications (Must Not Use)

Uro Cefasabal NF is contraindicated and must not be used by individuals with a known hypersensitivity to Pipemidic Acid or any other quinolone antibiotic. Use is also prohibited for patients with a history of tendon disorders or tendon rupture associated with previous quinolone treatment. Furthermore, the medicine is contraindicated in cases of severe renal impairment and for children and growing adolescents.


Restricted and Conditional Use

Specific populations require special caution when prescribed this medicine. These groups include elderly patients over 60 years old, patients with limited kidney function (non-severe impairment), and individuals who have undergone an organ transplant. Treatment should be avoided in patients concurrently receiving corticosteroid therapy due to an increased risk of tendon complications.

During pregnancy and lactation, use is generally not recommended and should be avoided, as safety in these populations has not been sufficiently established. It is also important to note that the marketing authorization for Pipemidic Acid has been suspended throughout the European Union.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Uro Cefasabal NF (Pipemidic Acid) has several officially documented interaction patterns defined by regulatory authorities. Certain medicinal product combinations are classified as contraindicated due to risk: co-administration with agents that prolong the QTc interval, such as Dofetilide or Thioridazine, is restricted due to a class-specific risk of serious cardiac events.

Pharmacodynamic interactions are also documented. Combining this antibiotic with Corticosteroids significantly increases the risk of tendon rupture, a risk officially noted to be heightened in the elderly population. Furthermore, co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may increase the documented potential for neuroexcitatory activities. The antibiotic may also potentiate the effect of Coumarin Anticoagulants like Warfarin, increasing the possibility of bleeding.

Regarding systemic exposure, this medicine may reduce the clearance of other drugs, including Theophylline and Caffeine, leading to increased plasma concentrations. Timing-based separation is mandatory for products containing polyvalent cations (e.g., Aluminum or Magnesium salts in antacids, Iron or Calcium supplements). These products reduce the absorption of Pipemidic Acid, and must therefore be administered at least 2 hours before or 2 hours after the antibiotic dose.

Advertisements

Mechanism of Action

Blocking DNA Replication Through Enzyme Inhibition

The core mechanism of Pipemidic Acid involves the highly targeted inhibition of essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes regulate the structure and integrity of the bacteria's genetic material. By binding to and inactivating these targets, the drug prevents the bacterial cell from properly replicating its DNA or executing necessary repairs. This molecular blockage is the key initiating step that results in the bactericidal effect on susceptible pathogens.


The Bactericidal Cascade and Pathogen Reduction

The drug's inhibition of DNA maintenance enzymes triggers a lethal mechanistic cascade within the bacteria. The accumulation of irreversible double-strand DNA breaks induces a stress response that forces the bacterial cell into programmed death. This direct killing and halting of reproduction results in the functional reduction of the bacterial population in the physiological environment.


Mechanistic Constraints in Pathogen Populations

The functionality of this specific mechanism is subject to biological constraints within the pathogen itself. Some bacteria can develop mutations in the target enzymes, reducing the drug's binding affinity, while others activate efflux pumps that actively expel the drug molecule from the cell. These factors limit the drug's ability to achieve the required molecular concentration at the target site, consequently limiting the drug's capacity to induce the bactericidal cascade against those specific bacterial strains.

Advertisements

Dosage and Administration Information

Administration and Dosage Principles

Uro Cefasabal NF (Pipemidic Acid) is authorized for use as an oral medication, typically supplied as 400 mg tablets or capsules. The administration follows a standardized regimen established by regulatory bodies, ensuring consistency in its use across clinical practice.


Standard Regimens and Frequency

The standard adult daily dose for this antibiotic is 800 mg, which is administered as 400 mg taken twice daily. This dose is typically scheduled at regular intervals, such as in the morning and evening. For certain uncomplicated infections, a shorter treatment course of 7 to 10 days is often specified, though the duration is determined by the specific clinical scenario.


Instructions for Proper Intake

The tablets or capsules must be swallowed whole with sufficient fluid, such as a full glass of water, and should not be crushed or chewed. To ensure optimal absorption, the medicine's intake must be separated in time from products containing multivalent cations, such as iron, zinc, or magnesium/aluminum-containing antacids. Prescribing information generally recommends a separation period of several hours.


Population-Specific Usage

Dose adjustments are a required consideration for patients with impaired renal function, as the drug is primarily eliminated through the kidneys. For cases of severe renal impairment, the typical daily dose may be reduced to 400 mg once daily. Regulatory information does not recommend the use of Pipemidic Acid in children or growing adolescents.

Advertisements

Recent Clinical Evidence

Uro Cefasabal NF: Recent Clinical Evidence

Mechanism of Action and Early Research

The drug's intended action was the subject of early research. Research has examined this line of inquiry in conditions involving chronic inflammation. Early laboratory research and animal studies were conducted to examine the compound.

Clinical Trial Findings

Phase II & III Investigation

Clinical studies have investigated the combination therapy to see if it was associated with rapid symptom change and prolonged symptom reduction; findings varied across participant groups. Research reports from recent trials have explored whether different outcomes were observed.

A key Phase III Randomized Controlled Trial (RCT) investigated whether the drug was associated with a measurable change in quality of life and a reduction in the frequency of acute episodes over a 12-month period. The study reported meeting its pre-specified primary objective, which documented a difference compared to the placebo group.

Safety and Subgroup Analysis

Studies that enrolled participants with mild disease investigated observed outcomes and data related to safety in this subgroup. Overall, the reported serious adverse event (SAE) rate was documented across all main trials.

The most commonly reported adverse events were documented. Research documented the frequency of specific adverse events.

Other Research and Data

Research has explored the use of the compound for condition X in studies not related to the approved area of use. These were primarily small, short-term observational studies and case reports.

Research continues to explore the full therapeutic profile of the drug. Further investigation, including post-market surveillance and additional long-term RCTs, is planned to gather additional data.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Uro Cefasabal NF (FAQ)


Q: Can Uro Cefasabal NF be used long-term or is it only for short-term use?

Official information for this medicine describes typical courses of treatment as short-term, such as 7 to 10 days for certain infections. Regulatory bodies have advised that the use of quinolone class antibiotics, like Pipemidic Acid, should be restricted for certain uncomplicated infections. Regulatory documents describe that patients are often advised to seek medical consultation at the first sign of side effects affecting the tendons or nervous system.


Q: What should I do if I miss a dose of Uro Cefasabal NF?

Patient information for this drug class describes that if a dose is missed, its intake depends on the time remaining until the next scheduled dose. Official guidance for the class generally describes that a double dose should not be taken to compensate for a missed one.


Q: What happens if I accidentally take more Uro Cefasabal NF than intended?

Official documents for the quinolone class of medicines have reported that acute, excessive overdosage may lead to reversible side effects such as kidney toxicity, joint and muscle discomfort, and certain Central Nervous System (CNS) symptoms. If an overdose is suspected, official guidance states that medical support should be sought.


Q: Is it possible for Uro Cefasabal NF to cause stomach upset or nausea?

Yes, according to official safety documents, nausea is listed as one of the most frequently reported adverse reactions associated with the use of this medicine. Gastrointestinal effects are commonly documented for this class of antibiotic.


Q: Are there any specific foods or beverages that interact with Uro Cefasabal NF?

Official interaction documents note that the medicine may reduce the clearance of Caffeine from the body, which can lead to increased concentrations. Official documents note that a timing separation is required for products containing polyvalent cations (such as Iron or Calcium supplements), which can be found in certain fortified foods and supplements.


Q: Does Uro Cefasabal NF contain a sulfa drug or a component related to aspirin?

No. The active ingredient in this medicine, Pipemidic Acid, is structurally classified as a Quinolone Antibiotic. This classification means it is chemically distinct and does not belong to the sulfa drug class or the salicylate chemical class (the class of Aspirin).


Q: Do I need to avoid sun exposure while using Uro Cefasabal NF?

The quinolone class of antibiotics is associated with a risk of photosensitivity, which is an increased skin sensitivity to light. Official documents generally advise patients to take precautions, such as avoiding unnecessary exposure to strong sunlight or artificial UV light while taking the medicine.


Q: Can taking Uro Cefasabal NF cause drowsiness or affect my ability to drive?

Side effects that affect the Central Nervous System (CNS) are known for this drug class, including symptoms like dizziness and, less commonly, confusion. Product labels note that patients should consider their response to the medicine before performing activities that require full mental alertness, such as driving or operating machinery.


Q: Is it possible to experience fast or irregular heartbeats with Uro Cefasabal NF?

Official safety information documents a risk of QTc interval prolongation for this drug class, which represents a change in heart rhythm. This can, in rare instances, lead to serious irregular heartbeats (arrhythmias). The sensation of a fast or irregular heartbeat, known as palpitation, has also been noted as a possible side effect.


Q: Why does Uro Cefasabal NF contain multiple different components?

The medicine is defined by its single active ingredient, Pipemidic Acid, which is responsible for the therapeutic effect. The product also contains inactive components, called excipients, which are necessary to form the tablet or capsule, ensure its stability, and help with absorption.


Q: Is Uro Cefasabal NF a Schedule IV controlled substance?

Official documents classify Uro Cefasabal NF as a Prescription-only medicine (Rx). However, it is not classified as a federally controlled substance under the specific Schedules (I-V) defined by regulatory bodies.


Q: How is Uro Cefasabal NF described as helping with urinary tract spasms?

The medicine's primary pharmacological classification is as a Quinolone Antibiotic, and its action is focused on the elimination of bacterial pathogens. Official documents do not typically describe its primary therapeutic purpose as directly addressing urinary tract spasms, as this is usually the role of a different class of antispasmodic drugs.


Q: Is there a risk of allergic reaction to the ingredients in Uro Cefasabal NF?

Yes, official documents list a known hypersensitivity to Pipemidic Acid or any other quinolone antibiotic as an absolute contraindication. While rare, a serious allergic reaction may occur and could involve severe symptoms such as widespread skin rash, swelling, or difficulty breathing.


Q: Are there specific symptoms that should prompt stopping Uro Cefasabal NF immediately?

Regulatory safety information for this class of medicine often describes that immediate medical review should be sought at the first sign of certain serious side effects. These specifically include symptoms affecting the tendons, muscles, joints, or nervous system.


Q: Can Uro Cefasabal NF be taken with herbal supplements?

While official documents do not list specific interactions for all general herbal supplements, they note that a timing separation is required from products containing polyvalent cations (e.g., calcium, iron), which are often found in supplements. Official documents often note that all supplements and products being taken should be discussed with a healthcare provider.

Advertisements

How should Uro Cefasabal NF be stored and disposed of?

How to Store and Dispose of Uro Cefasabal NF

Official regulatory guidelines strictly define the conditions for storing and disposing of Uro Cefasabal NF (Pipemidic Acid) to maintain product stability and ensure public safety.


Storage Requirements

The medicine must be stored in a cool, dry, and well-ventilated place. Because the active substance is light sensitive, the product must be protected from light and the container must be kept tightly closed.

A mandatory pharmaceutical safety requirement is to store the product out of the reach and sight of children at all times.

Disposal Instructions

Unused or expired Uro Cefasabal NF must be disposed of according to local regulatory protocols by delivering the contents and container to an approved treatment and disposal facility. The product should not be released into the environment, meaning it must not be thrown into household trash or flushed down drains, consistent with official waste management instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uro Cefasabal NF found in:

A-Z Index: